Top

Internal and Emergency Medicine

Published in:

01-04-2022 | COVID-19 | CE-Research Letter to the Editor

Prevalence and duration of symptoms among moderate and severe COVID-19 patients 12 months after discharge

Authors: C. Tortajada, A. Navarro, J. C. Andreu-Ballester, A. Mayor, S. Añón, J. Flores

Published in: Internal and Emergency Medicine | Issue 3/2022

Excerpt

Dear Editor, …

Available only for authorised users

O’Sullivan O (2021) Long-term sequelae following previous coronavirus epidemics. Clin Med (Lond) 21(1):e68–e70. https://doi.org/10.7861/clinmed.2020-0204CrossRef

Ahmed H, Patel K, Greenwood DC, Halpin S, Lewthwaite P, Salawu A, Eyre L, Breen A, O’Connor R, Jones A, Sivan M (2020) Long-term clinical outcomes in survivors of severe acute respiratory syndrome and Middle East respiratory syndrome coronavirus outbreaks after hospitalisation or ICU admission: A systematic review and meta-analysis. J Rehabil Med. https://doi.org/10.2340/16501977-2694CrossRefPubMed

Carfì A, Bernabei R, Landi F, Gemelli Against COVID-19 Post-Acute Care Study Group (2020) Persistent symptoms in patients after acute COVID-19. JAMA 324:603–605. https://doi.org/10.1001/jama.2020.12603CrossRefPubMedPubMedCentral

Huang C, Huang L, Wang Y, Li X, Ren L, Gu X, Kang L, Guo L, Liu M, Zhou X, Luo J, Huang Z, Tu S, Zhao Y, Chen L, Xu D, Li Y, Li C, Peng L, Li Y, Xie W, Cui D, Shang L, Fan G, Xu J, Wang G, Wang Y, Zhong J, Wang C, Wang J, Zhang D, Cao B (2021) 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet 397(10270):220–232. https://doi.org/10.1016/s0140-6736(20)32656-8CrossRefPubMedPubMedCentral

Klein H, Asseo K, Karni N, Benjamini Y, Nir-Paz R, Muszkat M, Israel S, Niv MY (2021) Onset, duration and unresolved symptoms, including smell and taste changes, in mild COVID-19 infection: a cohort study in Israeli patients. Clin Microbiol Infect 27(5):769–774. https://doi.org/10.1016/j.cmi.2021.02.008CrossRefPubMedCentral

Halpin SJ, McIvor C, Whyatt G, Adams A, Harvey O, McLean L, Walshaw C, Kemp S, Corrado J, Singh R, Collins T, O’Connor RJ, Sivan M (2021) Postdischarge symptoms and rehabilitation needs in survivors of COVID-19 infection: a cross-sectional evaluation. J Med Virol 93(2):1013–1022. https://doi.org/10.1002/jmv.26368CrossRefPubMed

Moreno-Pérez O, Merino E, Leon-Ramirez JM, Andres M, Ramos JM, Arenas-Jiménez J, Asensio S, Sanchez R, Ruiz-Torregrosa P, Galan I, Scholz A, Amo A, González-delaleja P, Boix V, Gil J, COVID 19-ALC Research Group (2021) Post-acute COVID-19 syndrome. Incidence and risk factors: a Mediterranean cohort study. J Infect 82(3):378–383. https://doi.org/10.1016/j.jinf.2021.01.004CrossRefPubMedPubMedCentral

Liang L, Yang B, Jiang N, Fu W, He X, Zhou Y, Ma WL, Wang X (2020) Three-month follow-up study of survivors of coronavirus disease 2019 after discharge. J Korean Med Sci. https://doi.org/10.3346/jkms.2020.35.e418CrossRefPubMedPubMedCentral

Tortajada C, Colomer E, Andreu-Ballester JC, Esparcia A, Oltra C, Flores J (2021) Corticosteroids for COVID-19 patients requiring oxygen support? Yes, but not for everyone: effect of corticosteroids on mortality and intensive care unit admission in patients with COVID-19 according to patients’ oxygen requirements. J Med Virol 93(3):1817–1823. https://doi.org/10.1002/jmv.26635CrossRefPubMed

10.

Goldberg D, Bridges K, Duncan-Jones P, Grayson D (1988) Detecting anxiety and depression in general medical settings. Br Med J 297:897. https://doi.org/10.1136/bmj.297.6653.897

11.

Mahler DA, Wells CK (1988) Evaluation of clinical methods for rating dyspnea. Chest 93(3):580–586. https://doi.org/10.1378/chest.93.3.580CrossRefPubMed

12.

EuroQol Research Foundation. EQ-5D-5L User Guide (2019) Available from: https://euroqol.org/publications/user-guides

13.

Tenforde MW, Kim SS, Lindsell CJ, Billig Rose E, Shapiro NI, Files DC, Gibbs KW, Erickson HL, Steingrub JS, Smithline HA, Gong MN, Aboodi MS, Exline MC, Henning DJ, Wilson JG, Khan A, Qadir N, Brown SM, Peltan ID, Rice TW, Hager DN, Ginde AA, Stubblefield WB, Patel MM, Self WH, Feldstein LR, IVY Network Investigators; CDC COVID-19 Response Team; IVY Network Investigators (2020) Symptom duration and risk factors for delayed return to usual health among outpatients with covid-19 in a multistate health care systems network—United States, March-June 2020. Morb Mortal Wkly Rep 69:993–998. https://doi.org/10.15585/mmwr.mm6930e1CrossRef

14.

Havervall S, Rosell A, Phillipson M, Mangsbo SM, Nilsson P, Hober S, Thålin C (2021) Symptoms and functional impairment assessed 8 months after mild covid-19 among health care workers. JAMA 325(19):2015–2016. https://doi.org/10.1001/jama.2021.5612CrossRefPubMedPubMedCentral

15.

Xiong Q, Xu M, Li J, Liu Y, Zhang J, Xu Y, Dong W (2021) Clinical sequelae of COVID-19 survivors in Wuhan, China: a single-centre longitudinal study. Clin Microbiol Infect 27(1):89–95. https://doi.org/10.1016/j.cmi.2020.09.023CrossRefPubMed

Title: Prevalence and duration of symptoms among moderate and severe COVID-19 patients 12 months after discharge
Authors: C. Tortajada
A. Navarro
J. C. Andreu-Ballester
A. Mayor
S. Añón
J. Flores
Publication date: 01-04-2022
Publisher: Springer International Publishing
Keywords: COVID-19
Post-COVID Syndrome
Fatigue
Published in: Internal and Emergency Medicine / Issue 3/2022
Print ISSN: 1828-0447
Electronic ISSN: 1970-9366
DOI: https://doi.org/10.1007/s11739-021-02895-6

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 3/2022

Survival of patients with idiopathic pulmonary fibrosis and pulmonary hypertension under therapy with nintedanib or pirfenidone

The presentations/physician ratio predicts door-to-physician time but not global length of stay in the emergency department: an Italian multicenter study during the SARS-CoV-2 pandemic

Communication and relationship at time of COVID-19: a possible heritage

Pharmaceutical patenting in the European Union: reform or riddance

Initial acuity of firearm injuries in the United States: are civilian injuries similar to combat casualty statistics

Emerging evidence for non-pharmacologic interventions in reducing the burden of respiratory illnesses

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage